PCI Biotech reports successful completion of second dose group in a Phase I/II Amphinex trial

Strong anti-tumour response observed in all patients

20-Jan-2010 - PCI Biotech reported that it has completed the treatment of the second dose group in the phase I/II study of its proprietary photosensitiser Amphinex® used in combination with the cytotoxic agent bleomycin in cancer patients. To date seven patients have been given a single photochemical ...

PCI Biotech strengthens the management team

06-Feb-2008 - PCI Biotech, Photocure's cancer-focused drug delivery subsidiary, strenghtens the management team and hires Per Walday as CEO. Mr Per Walday has been appointed as new CEO of PCI Biotech starting in the second quarter of 2008. Mr Anders Høgset, current CEO will take the position as Chief ...

Photocure announces plans to de-merge PCI Biotech

19-Nov-2007 - Photocure ASA announced that its Board of Directors has decided to a plan to de-merge PCI Biotech, its cancer-focused drug delivery subsidiary. Following the completion of the de-merger process, PCI Biotech intends to seek a public listing on the Oslo Stock Exchange. PCI Biotech has developed a ...

PCI Biotech file patents for combination of siRNA and the PCI technology

21-Mar-2007 - Photocure's daughter company PCI Biotech is developing a proprietary technology for site-specific drug delivery and drug enhancement called Photochemical Internalisation (PCI). PCI Biotech has, according to an agreement with Rikshospitalet-Radiumhospitalet HF, filed two patent applications ...